Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems

• US 20060204472A1
• Filed: 02/13/2004
• Published: 09/14/2006
• Est. Priority Date: 02/13/2003
• Status: Abandoned Application

• Current Assignee: Constantinos Paleos, Dimitrios Tsiourvas, National Centre of Scientific Research "Demokritos", Oreozili Sideratou
• Original Assignee: Constantinos Paleos, Dimitrios Tsiourvas, National Centre of Scientific Research "Demokritos", Oreozili Sideratou
• Inventors: Tsiourvas, Dimitrios, Sideratou, Oreozili, Paleos, Constantinos
• Application Number:
  US10/545,307
• Publication Number:
  US 20060204472A1
• Time in Patent Office: Days
• US Class Current: 424/78.270
• CPC Class Codes: A61K 47/6949 inclusion complexes, e.g. clathrates, cavitates or fullerenes
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C08G 83/002 Dendritic macromolecules
• CPC Class Codes: C08G 83/005 Hyperbranched macromolecules
• CPC Class Codes: C12N 15/88 using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

The present invention deals with the synthesis of multifunctional dendrimeric and hyperbranched polymers for application as drug delivery systems of bioactive pharmaceutical compounds and as gene delivery systems (carriers of genetic material), the latter through condensation with genetic material. Specifically, the present invention deals with the synthesis of multifunctional compounds based on appropriate dendrimeric or hyperbranched polymers at the terminal surface of which have been introduced functional groups X, Y, Z. In addition, for gene delivery to cells these multifunctional systems will become cationic for the formation of complexes with negatively charged genetic material. The functional groups render the delivery systems recognizable by complementary cell receptors. Furthermore they render the systems stable in the biological milieu and facilitate their transport through cell membranes.

Claims

1. A dendrimeric polymer with symmetric chemical structure or non-symmetric hyperbranched polymer, characterized in that the polymer is modified so as to comprise:

at least one atom of a chemical element able to form three or more chemical bonds

various different terminal functional groups bonded to said at least one atom, which terminal functional groups, together;

a) have low toxicity or no toxicity at all,

b) render the molecules of the above polymers recognizable from the complementary receptors of the cells,

c) render the polymers stable in a biological environment and

d) facilitate the transport of the said polymers through cell membranes.

2. A dendrimeric polymer or hyperbranched non-symmetric polymer according to the claim 1, which polymer is cationized for the formation of complexes with DNA when the said compounds are destined to be carriers of genetic material.

3. A dendrimeric polymer or hyperbranched non-symmetric polymer according to the claim 2, wherein the polymer is cationized by introducing ammonium, quaternary ammonium or guanidinium groups at the terminal groups of the dendrimer.

4. A dendrimeric polymer or hyperbranched non-symmetric polymer according to the claim 1 where the atom of a chemical element able to form three or more chemical bonds, is nitrogen, carbon or silicon.

5. A modified dendrimeric polymer according to the claim 1 which is a modified diaminobutane poly(propylene imino) dendrimer (DAB) or PAMAM dendrimer.

6. A modified hyperbranched non-symmetric polymer according to the claim 1, wherein the hyperbranched polymer is derived from the poly-condensation of an anhydride with a dialkyl amine.

7. A modified hyperbranched non-symmetric polymer according to the claim 1, wherein the hyperbranched polymer is derived from the anionic polymerization of epoxide derivatives with 1,1,1 tri(hydroxyalkyl)propane.

8. A modified hyperbranched non-symmetric polymer according to the claim 1, wherein the hyperbranched polymer is derived from the anionic polymerization of glycidol with 1,1,1 tri(hydroxymethyl)propane (PG-5).

9. A modified dendrimeric polymer or modified hyperbranched non-symmetric to polymer according to claim 1, wherein the functional groups include polymeric chains of diversified molecular weight at the surface of the dendrimeric polymeric or of the hyperbranched polymer.

10. A modified dendrimeric polymer or modified hyperbranched non-symmetric polymer according to claim 1, wherein the functional groups include at least one group that is complementary to a receptor site of a cell, a carbohydrate a folate, an RGD receptor, a nucleobase moiety or a barbiturate.

11. A modified dendrimeric polymer or modified hyperbranched non-symmetric polymer according to claim 1, wherein the functional groups include at least one group that facilitates the transport of the dendrimeric polymer or modified hyperbranched polymer together with any encapsulated active drug ingredient or genetic material through a cell membrane, e.g. a guanidinium as moiety, an oligoarginine or polyarginine derivative or a polypropylene oxide moiety.

12. A modified dendrimeric polymer or modified hyperbranched non-symmetric polymer according to claim 1, wherein the functional groups include at least one targeting ligand, a carbohydrate, a folate, an RGD receptor, a nucleobase moiety or a barbiturate.

13. A dendrimeric polymer or hyperbranched non-symmetric polymers according to claim 1, including an encapsulated bio-active pharmaceutical compound or carrying genetic material.

14. A dendrimeric polymer or hyperbranched non-symmetric polymer according to claim 1, wherein the bio-active pharmaceutical compound is betamethasone or a betamethasone derivative.

15. A method for the synthesis of a multi functional dendrimer or hyperbranched polymer according to claim 1 which method is characterized in that the surface of these polymers is modified in steps that comprise:

a) Substitution of the amino groups or other toxic groups of the surface with hydroxy, carboxylic or quaternary ammonium groups or other non-toxic groups

b) Introduction of polymeric chains of diversified molecular weight at the surface of the dendrimeric carriers or of the hyperbranched polymers, as for instance of poly(ethyleneglycol) (PEGylation) so that the polymers are thus protected from the MPS (Mononuclear Phagocyte System) of the organism.

c) Introduction of recognizable groups complementary to the receptors or to the tissues, carbohydrate moieties, folate or RGD receptor, nucleobase moieties or barbiturate group, so as to enhance the targeting ability of the carrier, and

d) Introduction of groups that facilitate the transport of the carriers together with the encapsulated bio-active pharmaceutical compound through cell membranes, such as guanidinium moieties, oligo-arginine or poly-arginine derivatives or polypropylene oxide moieties.

16. A method according to claim 15 where

the initial reaction of external amino or hydroxy groups of dendrimers or hyperbranched polymers is performed with appropriate protective polymers, bearing reactive groups at one end such as isocyanate, epoxide or N-hydroxysuccinimide,

subsequent reaction of the greatest portion of amino groups of the obtained polymer is performed with ethylisocyanate for the replacement of toxic amino groups,

subsequent-reaction of the previously obtained polymer for the transformation of amino groups to recognizable groups as for example guanidinium groups,

subsequent introduction of a group or groups which facilitate the transport of the carriers through cell membranes as for instance polyarginine or propyleneoxide chains.

17. A method according to claim 15, which method is characterized in that the said polymers are cationized for the formation of complexes with DNA.

18. A method according to claim 15, which method is characterized in that when the toxic group of the surface is an amino group, a aliphatic chain having less than eight carbon atoms, preferably two or three carbon atoms, is introduced for its replacement.

19. A pharmaceutical formulation characterized in that it comprises a bio-active pharmaceutical compound or genetic material encapsulated in a modified multi-functional dendrimeric or modified multi-functional hyperbranched non-symmetric polymer according to claim 1.

20. A method for producing a pharmaceutical formulation for delivering a bio-active pharmaceutical compound or genetic material, which method comprises synthesizing a polymer according to claim 15 and encapsulating the bio-active pharmaceutical compound or genetic material therewith.

21. A modified dendrimeric polymer or a modified hyperbranched non-symmetric polymer according to claim 1 that includes an encapsulated bio-active pharmaceutical compound or that carries genetic material for use in therapy.

22. Use of a modified dendrimeric polymer or a modified hyperbranched non-symmetric polymer according to claim 1 that includes an encapsulated bio-active pharmaceutical compound or that carries genetic material in therapy, for manufacture of a pharmaceutical dosage form.

23. Use of a modified dendrimeric polymer or a modified hyperbranched non-symmetric polymer according to claim 1 that includes an encapsulated bio-active pharmaceutical compound or that carry genetic material in the manufacture of a medicament for treating the same disease or condition as the compound or the genetic material.

24. A modified hyperbranched non-symmetric polymer according to the claim 6 wherein the anhydride is succinic anhydride, phthallic anhydride or tetrahydrophthalic anhydride and the dialkyl amine is diisopropylamine.

25. A modified hyperbranched non-symmetric polymer according to the claim 9 wherein the polymeric chains are polyalkyl glycol or poly(ethyleneglycol).

26. A modified hyperbranched non-symmetric polymer according to the claim 10 wherein the cell is a guanidinium group, the carbohydrate is mannose, glycose, or galactose, and the nucleobase moiety is adenine, thymine, guanine, or cytosine.

27. A modified hyperbranched non-symmetric polymer according to the claim 12 wherein the targeting ligand is guanidinium group, the carbohydrate is mannose, glycose, or galactose, and the nucleobase moiety is adenine, thymine, guanine, or cytosine.